Stem cell or bone marrow transplant is a way of giving very high dose chemotherapy. This treatment aimsto cure some types of cancer, including Hodgkin lymphoma.

Bone marrow is a spongy material that fills the bones.

It contains early blood cells, called stem cells. These develop into the 3 different types of blood cell.

You have a stem cell or bone marrow transplant after very high doses of chemotherapy. The chemotherapy has a good chance of killing the cancer cells but also kills the stem cells in your bone marrow.

Before your high dose chemotherapy, your team collects your stem cells or bone marrow. Or they collect adonor's stem cells or bone marrow. After the treatment you have the cells into a vein through a drip. The cells find their way back to your bone marrow. Then you can make the blood cells you need again.

You might have this intensive treatment if your Hodgkin lymphoma comes back after the first course of treatment. It can get rid of the lymphoma again for many people. Your doctor might also suggest this treatment if your Hodgkin lymphoma has not responded to the standard treatment.

You might have a course of high dose BEAM or LEAM chemotherapy. Then most people with Hodgkin lymphoma have their own stem cells or bone marrowback after the high dose treatment. This is called an autologous transplant.

You're now more likely to have a stem cell transplant (also called peripheral blood stem cell transplant) than a bone marrow transplant.

This is because:

You have injections of growth factors before, and sometimes after, the stem cell transplant. Growth factors are natural proteins that make the bone marrow produce blood cells.

You have daily injections of growth factor for between 5 and 10 days. Sometimes you might have low doses of chemotherapy with the growth factor injections.

After your growth factor injections, you have blood tests every day to see if there are enough stem cells in your bloodstream. When there are enough cells, you have them collected. This is called harvesting. Collecting the stem cells takes 3 or 4 hours. You are awake during this process. You lie down on a couch. Your nurse puts a drip into each of your arms and attaches it to a machine.

Your blood passes out of one drip. It goes through the machine and back into your body through the other drip. The machine filters the stem cells out of your blood. They are collected and frozen until after your high dose treatment.

You mayneed to go back the following day for a second harvest if they don'thaveenough cells from the first collection.

You might feel very tired after having your stem cell collection.

You might have:

This happens if your calcium level gets low during your collection. Your nurses will give you extra calcium through a drip if this happens.

You have your bone marrow taken (bone marrow harvest) under a general anaesthetic. This means you are asleep and can't feel anything during the procedure.

You lie on your side on a couch. Your doctor puts a needle through your skin into the hip bone (pelvis). The doctor gently draws out the bone marrow through the needle into a syringe. To get enough bone marrow the doctor needs to put the needle into several parts of the pelvis. You have about 2 pints (1 litre) of bone marrow taken out and then it's frozen until it's needed.

You might have a stem cell or bone marrow transplant using cells from a donor. This is called an allogeneic transplant. The cells need to be as similar as possible to yours.

So these can be from:

Youmight have bone marrow from a donor if:

Doctors are still learning how best to use allogeneic transplants for Hodgkin lymphoma.

The side effects of having a stem cell or bone marrow transplantare caused by high dose chemotherapy.

The main side effectsinclude:

You can call the Cancer Research UK nurses to talk about any worries you might have about having a transplant. The number is freephone 0808 800 4040, and the lines are open Monday to Friday, 9am to 5pm.

Visit link:
Stem cell and bone marrow transplants - Cancer Research UK

Bone marrow donation is one of two methods of collecting blood forming cells for bone marrow transplants. Bone marrow donation is a surgical procedure that takes place in a hospital operating room. Doctors use needles to withdraw liquid marrow (where the bodys blood-forming cells are made) from both sides of the back of your pelvic bone. You will be given anesthesia and feel no pain during the donation. After donation, your liquid marrow is transported to the patients location for transplant.

Typically, the hospital stay for marrow donation is from early morning to late afternoon, or occasionally overnight for observation. The donation will take place in a hospital that is experienced and participates in marrow collections for Be The Match.

Common side effects of marrow donation reported 2 days after donation: Back or hip pain 84%, Fatigue 61%, Throat pain 32%, Muscle pain 24%, Insomnia 15%, Headache 14%, Dizziness 10%, Loss of appetite 10%, Nausea 9%.

The median time to full recovery for a marrow donation is 20 days. Recovery after marrow donation: 5% - 2 days, 18%-7 days, 71%-30 days, 97%-180 days, 99%-1 year

Learn more about what happensafter you donate.

Continue reading here:
Donating Bone Marrow Experience | Be The Match

SAN DIEGO, Nov. 21, 2022 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that Dan Faga, interim chief executive officer of AnaptysBio, will represent the company in a fireside chat at the Piper Sandler 34th Annual Healthcare Conference on Tuesday November 29th, 2022, at 8:10 a.m. ET / 5:10 a.m. PT.

Link:
AnaptysBio to Participate at the Piper Sandler 34th Annual Healthcare Conference

Company Announcement

Read more:
Grant of Restricted Stock Units to Board Members and Employees and Grant of Warrants to Employees in Genmab

Daix (France), Long Island City (New York, United States), November 21, 2022 – Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of nonalcoholic steatohepatitis (NASH) and other diseases with significant unmet medical needs, today announces that, effective on November 9th, 2022, Inventiva’s board of directors coopted Dr. Lucy Lu as the Director of its Board of Directors in lieu of Sofinnova Partners.

Read more:
Inventiva announces a new Director of the Board of Directors

BURLINGTON, Mass., Nov. 21, 2022 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, today announced a proposed underwritten public offering of shares (“Shares”) of its common stock (the “Offering”). All Shares to be sold in the Offering will be offered by scPharmaceuticals. The Offering is subject to market and other conditions, and there can be no assurance as to whether or when the Offering may be completed, or as to the actual size or terms of the offering.

More:
scPharmaceuticals Announces Proposed Underwritten Public Offering of Common Stock

ERYTECH Provides Business and Financial Update for the Third Quarter of 2022

Visit link:
ERYTECH Provides Business and Financial Update for the Third Quarter of 2022

PORTLAND, Maine, Nov. 21, 2022 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically-proven and practical products that improve the health and productivity of dairy and beef cattle, today announced its unaudited financial results for the quarter ended September 30, 2022.

Link:
ImmuCell Announces Unaudited Financial Results for the Quarter Ended September 30, 2022

EMERYVILLE, Calif., Nov. 21, 2022 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT), a clinical-stage biotherapeutics company harnessing the power of directed evolution for targeted genetic medicines, announced that David Kirn, M.D., Co-Founder and Chief Executive Officer of 4DMT, will participate in a fireside chat at the Evercore ISI HealthCONx 2022 Conference. The fireside chat will take place on Wednesday, November 30, 2022 at 3:55 p.m. ET.

Go here to read the rest:
4D Molecular Therapeutics to Participate in the Upcoming Evercore ISI HealthCONx 2022 Conference

SAN DIEGO and SUZHOU, China, Nov. 21, 2022 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company transforming the discovery and development of antibody-based therapies, today announced the appointment of Cuong Do, MBA, to Adagene’s board of directors (the “Board”) as an independent director. He will also serve as an audit committee member.

Follow this link:
Adagene Appoints Cuong Do to Board of Directors and Audit Committee

CAMBRIDGE, Mass., Nov. 21, 2022 (GLOBE NEWSWIRE) -- Third Harmonic Bio, Inc. (Nasdaq: THRD), a clinical-stage biopharmaceutical company focused on advancing the next wave of medicine for allergy and inflammation, today announced that Chief Executive Officer Natalie Holles will participate in a fireside chat at the Evercore ISI 5th Annual HealthCONx Conference on Thursday, November 29, 2022, from 10:05-10:25 a.m. ET.

See the rest here:
Third Harmonic Bio to Participate in Fireside Chat at the Evercore ISI 5th Annual HealthCONx Conference

BOSTON, Nov. 21, 2022 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases and other public health threats for civilian, government and military use, today announces that Evan Loh, M.D., chief executive officer, will participate in a fireside chat at the 5th Annual Evercore ISI HealthCONx Conference on Wednesday, Nov. 30 at 9:15 a.m. ET.

Continue reading here:
Paratek Pharmaceuticals to Present at the 5th Annual Evercore ISI HealthCONx Conference

SEATTLE, Nov. 21, 2022 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will be participating in the upcoming Piper Sandler Healthcare Conference in New York, NY.

More here:
Adaptive Biotechnologies to Participate in the Piper Sandler Healthcare Conference

FREMONT, Calif., Nov. 21, 2022 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB), today announced the company will be participating in the upcoming Piper Sandler Healthcare Conference in New York, NY.

See the article here:
Cytek Biosciences to Participate in the Piper Sandler Healthcare Conference

BALA CYNWYD, Pa., Nov. 21, 2022 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that company management will present and participate in 1x1 investor meetings at the 34th Annual Piper Sandler Healthcare Conference, which is taking place in New York, NY from November 29 – December 1, 2022. The Company’s presentation will take place on Thursday, December 1, 2022, at 10:10 AM ET.

Read more:
Larimar Therapeutics to Present at the 34th Annual Piper Sandler Healthcare Conference

MALVERN, Pa., Nov. 21, 2022 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ:STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, today announced that Keith Sullivan, President and Chief Executive Officer, and Steve Furlong, Senior Vice President, Chief Financial Officer, and Treasurer, will participate in the Piper Sandler 34th Annual Healthcare Conference on Thursday, December 1, 2022. The Company is scheduled to present at the conference at 9:30 am Eastern Time the same day via webcast.A live audio webcast of the conference presentation will be available online at the investor relations page of the Company’s website at ir.neuronetics.com. A replay of the webcast will be archived on the website for approximately 90 days.About NeuroneticsNeuronetics, Inc. believes that mental health is as important as physical health. As a global leader in neuroscience, Neuronetics is redefining patient and physician expectations with its NeuroStar Advanced Therapy for Mental Health. NeuroStar is a non-drug, noninvasive treatment that can improve the quality of life for people suffering from neurohealth conditions when traditional medication hasn’t helped. NeuroStar is FDA-cleared for adults with major depressive disorder (MDD), as an adjunct for adults with obsessive-compulsive disorder (OCD), and to decrease anxiety symptoms in adult patients with MDD that may exhibit comorbid anxiety symptoms (anxious depression). NeuroStar Advanced Therapy is the leading transcranial magnetic stimulation (TMS) treatment for MDD in adults with over 4.8 million treatments delivered. NeuroStar is backed by the largest clinical data set of any TMS system for depression, including the world’s largest depression Outcomes Registry. Neuronetics is committed to transforming lives by offering an exceptional treatment that produces extraordinary results. For safety and prescribing information, www.neurostar.com.Investor Contact:Mark KlausnerWestwicke Partners443-213-0501ir@neuronetics.comMedia Contact:EvolveMKD646.517.4220NeuroStar@evolvemkd.com

See the original post:
Neuronetics to Present at the Piper Sandler 34th Annual Healthcare Conference

SOUTH SAN FRANCISCO, Calif., Nov. 21, 2022 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing novel T cell engagers, today announced that management will participate in a fireside chat at the Piper Sandler 34th Annual Healthcare Conference. The discussion will take place on Wednesday, November 30, 2022 at 1:00 p.m. ET (10:00 a.m. PT).

Follow this link:
Harpoon Therapeutics to Participate in the Piper Sandler 34th Annual Healthcare Conference

DURHAM, N.C., Nov. 21, 2022 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) ("Bioventus" or "the Company"), a global leader in innovations for active healing, today amended its previously announced financial results for the three and nine months ended October 1, 2022.

Continued here:
Bioventus Issues Revised Third Quarter Results; Updates Full-Year 2022 Financial Guidance

ADELAIDE, Australia, Nov. 21, 2022 (GLOBE NEWSWIRE) -- Bionomics Limited (ASX: BNO, Nasdaq: BNOX), (“Bionomics” or the “Company”), a clinical-stage biopharmaceutical company developing novel, allosteric ion channel modulators designed to transform the lives of patients suffering from serious central nervous system (“CNS”) disorders with high unmet medical need, today announced the closing of an underwritten public offering in the United States (the “Offering”) of 641,026 American Depositary Shares (“ADSs”), each representing 180 ordinary shares of Bionomics, at a public offering price of US$7.80 per ADS.

More here:
Bionomics Limited Announces Closing of US$5 Million Underwritten Offering of American Depositary Shares in the United States

Award from Leading Life Science Forum Championing Sector Collaboration for Novel Solutions that Address Pressing Health Challenges is the Community’s Highest Honor

See the rest here:
National Public Health Leader Reed Tuckson, MD, Managing Director, Tuckson Health Connections, and Health Innovation Executive Vlad Coric, MD, CEO,...